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Abstract
The effectiveness of phosphate binders can be assessed by evaluating urinary phosphorus excretion in healthy vol-
unteers, which indicates the ability of the phosphate binder to reduce gastrointestinal phosphate absorption. Healthy
volunteers were enrolled into one of ﬁve separate randomized trials; four were open label and one double blind. Follow-
ing a screening period of ≤28 days, participants received differing tablets containing lanthanum carbonate [LC, 3000
mg/day of elemental lanthanum (in one study other doses were also used)]. Participants received a standardized phos-
phate diet and remained in the relevant study center throughout the duration of each treatment period. The end point in
all studies was the reduction in urinary phosphorus excretion. Reductions in mean 24-h urinary phosphorus excretion
in volunteers receiving a lanthanum dose of 3000 mg/day were between 236 and 468 mg/day over the ﬁve sepa-
rate studies. These data in healthy volunteers can be used to estimate the amount of reduction of dietary phosphate
absorption by LC. The reduction in 24-h urinary phosphorus excretion per tablet was compared with published data
on other phosphate binders. Although there are limitations, evidence suggests that LC is a very effective phosphate
binder in terms of binding per tablet.
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INTRODUCTION
Phosphate binders are usually required to restore phos-
phate balance in patients with advanced chronic kid-
ney disease (CKD). The effectiveness of such binders
depends on their ability to bind dietary phosphate in the
gut and the stability of the resulting insoluble complex in
the presence of normal contents of the gastrointestinal
tract, thus preventing absorption. Several phosphate
binders are currently available, including calcium-based
agents (calcium carbonate and calcium acetate). How-
ever, calcium-based agents may increase calcium load
and the risk of vascular calciﬁcation.1–3
Lanthanum carbonate [(LC) FOSRENOL, Shire
Pharmaceuticals, Basingstoke, UK], sevelamer
hydrochloride [(SH) Renagel, Genzyme Therapeu-
tics, Cambridge, MA, USA], and sevelamer carbonate
(Renvela, Genzyme Therapeutics, Cambridge, MA,
USA) are non-calcium-containing phosphate binders
licensed for use in CKD patients.4–6 In vitro data indi-
cate that LC has a higher binding afﬁnity for phosphate
than SH and LC’s phosphate binding is not affected by
acidity or the presence of bile acids.7
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In healthy people and patients with the early stages of
CKD, serum phosphorus levels are maintained within
the normal range by complex homeostatic mechanisms
with the kidney as one of the main regulatory organs for
maintenance of phosphate balance.8 As such individuals
are in neutral phosphate balance, measurement of uri-
nary phosphorus excretion can be used as an estimate
of intestinal phosphate absorption.5
This article presents results from ﬁve healthy volun-
teer studies examining the ability of LC to bind dietary
phosphate.
MATERIALS AND METHODS
Trial Designs
Each randomized trial of healthy volunteers was a single
center study; studies 1, 2, and 3 were in UK centers;
study 4 was in a center in the United States; and study
5 was in a center in Japan. All were carried out in
accordance with the principles of the 18th World Med-
ical Assembly (Helsinki 1964) and amendments, and
local ethical and legal requirements. Informed consent
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Table 1. Summary of studies of lanthanum carbonate (LC).
Study Description n
Phosphorus
intake (mg/day) Treatments (doses) Details
Study 1 Parallel-group,
dose-ranging
study
70 ∼2000 LCa
• 750 mg/day
• 1500 mg/day
• 3000 mg/day
• 4500 mg/day
• 6000 mg/day
Control
• Taken with 200 mL water
• Three times daily for 6 days, with one dose
g i v e no nt h em o r n i n go fd a y7
• Average 24-h urinary phosphorus excretion
was calculated for the 3 days before dosing
(baseline) and the ﬁnal 3 days of treatment
Study 2 Three-way crossover,
pharmacodynamic
equivalence study
56 Standard LC • Taken with 400 mL water
• 3000 mg/daya
◦ 4 × 250 mg
◦ 2 × 500 mg
◦ 1 × 1000 mg
All three times daily
• Three times daily for 3 days, with one dose
g i v e no nt h em o r n i n go fd a y4
• At least 14 days washout was allowed
between treatment periods
• Average 24-h urinary phosphorus excretion
was calculated for the day before dosing
(baseline) and the 3-day treatment periods
Study 3 Two-way crossover,
alternative
formulation study
52 ∼1300 LC
• 3000 mg/daya
◦ 4 × 250 mg
◦ 1 × 1000 mg new
formulation
All three times daily
• Taken with 200 mL water
• Three times daily for 3 days, with one dose
g i v e no nt h em o r n i n go fd a y4
• At least 14 days washout between treatment
periods
• Average 24-h urinary phosphorus excretion
was calculated for the 2 days before dosing
(baseline) and the 3-day treatment periods
Study 4 Two-way crossover,
optimized
formulation study
57 ∼1300 LC • Taken with 240 mL water
• 3000 mg/daya (4 × 250 mg
three times daily)
• Three times daily for 3 days, with one dose
g i v e no nt h em o r n i n go fd a y4
◦ Optimized formulation
(batch A)
• At least 10 days washout between treatment
periods
◦ Alternative formulation
(batch B)
• Average 24-h urinary phosphorus excretion
was calculated for the 2 days before dosing
(baseline) and the 3-day treatment periods
Study 5 Parallel-group,
placebo-controlled
study
9 ∼1200 LC
• 3000 mg/daya
◦ 4 × 250 mg, three
times daily
• Matching placebo
• Taken with 150 mL water
• Three times daily for 5 days
• 24-h urinary phosphorus excretion was
calculated on the day before dosing
(baseline) and compared with that on the
ﬁnal day of treatment
Note: aElemental lanthanum.
was obtained from all volunteers. In all studies (abbre-
viated details in Table 1), volunteers were random-
ized following a screening period of up to 28 days
and participants remained in the study centers for the
study period only and not during washout periods.
Restrictions on concomitant medication use occurred
in each study. The only permitted medications were
hormonal contraceptives and treatments required for
adverse events. Vitamin supplements were excluded
during the studies. Study 5 was a double-blind study
and studies 1–4 were all open label.
Study 1
This parallel-group study involved 70 volunteers ran-
domized to receive one of six treatments. LC at ﬁve
different daily doses—1 × 250 mg tablet, 1 × 500 mg
tablet, 1 × 1000 mg tablet, 2 × 750 mg tablets, and
2 × 1000 mg tablets—with 200 mL of water three
times daily (elemental lanthanum: 750, 1500, 3000,
4500, 6000 mg) was compared with control. Partici-
pants entered the unit 8 days before ﬁrst dosing and
received their LC tablet(s) with 200 mL water three
times daily for 6 days with one dose given on the
morning of day 7. Study participants received a stan-
dardized phosphate diet throughout the study period
(approximately 2000 mg of elemental phosphorus per
day). The primary objective was to investigate the rela-
tionship between LC dose and urinary phosphorus
excretion. The highest dose of 6000 mg was used to
assess the potential maximum dose for clinical use.
Study 2
This study was designed to establish pharmacodynamic
equivalence of equal doses of three different tablet
strengths of LC. Reducing the number of tablets a
patient requires each day may improve patient com-
pliance. Under the three-way crossover study design,
56 volunteers were randomized into six treatment
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sequences, with at least nine volunteers per sequence,
immediately before the ﬁrst dose of the study. Individ-
uals received 1000 mg of elemental lanthanum either
as 4 × 250 mg LC tablets or 2 × 500 mg tablets or
1 × 1000 mg tablet with 400 mL of water three times
daily for 3 days and one dose in the morning of day 4.
There were three treatment periods of 4 days’ dosing
with at least 14 days washout period between the last
dose of each treatment period and the ﬁrst dose of the
subsequent treatment period. A standard menu was fol-
lowed to ensure the same daily phosphate intake for each
treatment period.
Study 3
In this crossover study, 52 volunteers were random-
ized to two treatment sequences to receive 1000 mg of
elemental lanthanum, in one of two alternative formu-
lations, either as the (at the time) existing formulation
of 4 × 250 mg LC tablets or a new formulation of
1 × 1000 mg tablet with 200 mL of water three times
daily for 3 days and one dose in the morning of day 4.
Following a washout period of at least 14 days, partici-
pants crossed over to the alternative LC formulation for
4 days’ dosing. Study volunteers received a standardized
phosphate diet throughout the study period (approxi-
mately 1300 mg of elemental phosphorus per day).
Study 4
Fifty-seven volunteers were randomized to one of two
treatment sequences to receive tablets with two dif-
ferent dissolution characteristics (batch A: optimized
formulation or batch B: alternative formulation) in a
crossover study. Tablets in batch A passed a 10 dips/min
dissolution test, whereas tablets in batch B failed 10 and
20 dips/min dissolution tests and passed a 30 dips/min
dissolution test. Participants received 1000 mg of ele-
mental lanthanum as 4 × 250 mg of LC tablets
with 240 mL water three times daily for 3 days, with
4 × 250 mg dose given in the morning of day 4. After
a washout period of at least 10 days between dosing
periods, volunteers crossed over to the other batch. Dur-
ing study periods, individuals received a standardized
phosphate diet (approximately 1300 mg of elemental
phosphorus per day).
Study 5
This placebo-controlled, parallel-group study involved
nine Japanese healthy volunteers randomized into one
of two groups. Participants received either 1000 mg of
elemental lanthanum as 4 × 250 mg LC tablets with
150 mL water three times daily or matching placebo for
5 days. During the study periods individuals received
a standard phosphate diet (approximately 1200 mg of
elemental phosphorus per day).
Diets
Participants consumed food from phosphate-
standardized menus while resident in study centers. LC
was taken during or immediately after consumption
of the standard meals. No other phosphate-containing
foods or drinks were permitted during treatment
periods.
Urine Collection
All urine samples were collected for 24-h periods start-
ing and ending before the morning dose of LC. During
collection, urine was stored at 4◦C. The total urine vol-
ume over the collection period was recorded. Aliquots
were transferred into polypropylene containers and
stored frozen (−20◦C) before analysis of phosphorus
concentration by colorimetric methods.
Assessments
In each study, 24-h urinary phosphorus excretion was
measured in the pharmacodynamic population using
methods consistent with those used previously to deter-
mine the phosphate-binding capacity of SH.5 Any par-
ticipant who vomited during the days that measurement
of 24-h urinary phosphorus excretion was being made
was excluded from studies 1–4.
In study 1, baseline assessments were made in the
3 days before dosing and treatment was given from
days 8 to 13 and on the morning of day 14. In this
study, 24-h urinary phosphorus excretion was mea-
sured in the ﬁnal 3 days of treatment. Although the
dosing period was longer in this study, the end point
was still the average daily urinary phosphorus excre-
tion over 3 days of the treatment period. In study 2,
24-h urinary phosphorus excretion was measured the
day before ﬁrst dosing, on each dosing day, and for 48 h
after dosing. The end point for assessment of pharma-
codynamics in study 2 was the average daily reduction
in urinary phosphorus excretion during the 3-day LC
treatment period. In study 3, 24-h urinary phosphorus
excretion was measured for 2 days before dosing and
the 3 days of full dosing. The end point was the aver-
age level of daily urinary phosphorus excretion during
the 3-day LC treatment period. In study 4, measure-
ment of 24-h urinary phosphorus excretion was made
for 48 h before the ﬁrst dose and then on each day
of dosing. The end point was the average daily urinary
phosphorus excretion over the 3-day dosing period. In
study 5, 24-h urinary phosphorus excretion was mea-
sured the day before dosing, on each of the 5 dosing
days, and for 48 h after the ﬁnal day of dosing. The
reduction in 24-h urinary phosphorus excretion during
the ﬁnal day of dosing was compared with baseline. In
summary, studies 1–4 all had the reduction in 24-h uri-
nary phosphorus excretion averaged over 3 days as the
end point. Only in study 5 was the end point reduction
in urinary phosphorus excretion based on just the value
of 1 day.
Adverse events, physical examination, vital signs, and
clinical laboratory tests were assessed during screen-
ing and throughout each study. Serum phosphorus and
calcium levels were also assessed during the studies.
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Statistical Methods
The safety population was deﬁned as all participants
who were randomized and received at least one dose
of study medication in all studies. The pharmacody-
namic population in studies 1, 3, and 4 included all
individuals in the safety population who completed all
urine collections in all treatment groups and consumed
at least 95% of food in all treatment periods. The phar-
macodynamic population in studies 2 and 5 included all
individuals in the safety population who completed all
urine collections in all treatment groups.
The end points of studies 2, 3, and 4 were analyzed
using a mixed effects linear model with sequence, treat-
ment (or batch for study 4), and period as ﬁxed effects,
and subject within sequence as a random effect. In stud-
ies 2 and 3, baseline was also included as a covariate. An
analysis of variance with treatment as a factor was used
in study 1. In study 5, the reductions in 24-h urinary
phosphorus within each treatment group were analyzed
using a paired t-test.
RESULTS
Baseline characteristics of volunteers in the safety
population of treatment groups in study 1 are listed in
Table 2. The baseline characteristics of volunteers in the
safety population of all ﬁve studies are listed in Table 3.
The number of volunteers included in the pharma-
codynamic population in the three crossover studies
was 47, 48, and 33 in studies 2, 3, and 4, respectively.
In study 1, nine volunteers were included in the
pharmacodynamic population receiving a daily dose of
3000 mg LC, whereas in study 5, six volunteers were
included in the pharmacodynamic population receiving
LC.
24-h Urinary Phosphorus Excretion
All ﬁve LC groups in study 1 showed a decrease from
baseline in urinary phosphorus excretion values, with
the highest dose groups (3000–6000 mg/day) showing
the greatest change (Figure 1).
Reductions in mean 24-h urinary phosphorus excre-
tion from baseline in the pharmacodynamic population
with a LC dose of 3000 mg/day across all ﬁve studies are
shown in Table 4. This LC dose reduced urinary phos-
phorus levels by between 236 and 468 mg/day (7.6–15.1
mmol/day). In those studies where they were directly
compared, the different LC formulations were shown
to be pharmacodynamically equivalent. As expected,
homeostasis was maintained by the normal kidney func-
tion in healthy volunteers; therefore, LC treatment
was not associated with clinically signiﬁcant changes
in serum phosphorus or calcium levels in any of the
studies.
Tolerability
Overall, LC was well tolerated and there were no seri-
ous adverse events in any of these studies. There was
no evidence of any dose-related increase in adverse
events across the LC groups in study 1. Most adverse
events across the LC groups in study 1 were mild in
intensity and the most common were headache, nausea,
and abdominal pain. With regard to treatment-related
adverse events, gastrointestinal disorders (nausea or
vomiting) were experienced by two (20%) participants
and headache was experienced by one individual (10%)
in the group receiving an elemental LC dose of 3000
mg/day in study 1. In study 2, the most common adverse
event was nausea, which was experienced by six (12%)
volunteers receiving the reference (4 × 250 mg tablets)
Table 2. Baseline characteristics for study 1 at total doses of 750, 1500, 3000, 4500, and 6000 mg lanthanum per day and control.
Parameter 750 mg/day 1500 mg/day 3000 mg/day 4500 mg/day 6000 mg/day Control
n 10 10 10 10 10 10
Age, mean ± SD
(range) (years)
26.1 ± 5.7
(20–38)
27.2 ± 7.4
(18–42)
25.4 ± 5.2
(20–37)
23.9 ± 3.0
(20–28)
23.4 ± 3.4
(20–31)
25.9 ± 3.8
(19–31)
Gender
Male 6 (60.0) 7 (70.0) 6 (60.0) 1 (10.0) 2 (20.0) 4 (40.0)
Female 4 (40.0) 3 (30.0) 4 (40.0) 9 (90.0) 8 (80.0) 6 (60.0)
Race
Caucasian 9 (90.0) 9 (90.0) 9 (90.0) 9 (90.0) 8 (80.0) 10 (100.0)
Black 0 (0) 0 (0) 0 (0) 1 (10.0) 0 (0) 0 (0)
Asian 1 (10.0) 1 (10.0) 1 (10.0) 0 (0) 1 (10.0) 0 (0)
Other 0 (0) 0 (0) 0 (0) 0 (0) 1 (10.0) 0 (0)
Weight, mean ± SD
(range) (kg)
73.5 ± 8.3
(60–83)
70.8 ± 13.9
(51–93)
72.3 ± 12.6
(54–91)
69.8 ± 10.7
(56–85)
63.8 ± 9.6
(54–81)
68.9 ± 6.5
(56–76)
Serum phosphorus,
mean ± SD
(range) (mg/dL)
4.1 ± 0.3
(3.7–5.0)
3.9 ± 0.4
(3.4–4.3)
4.1 ± 0.4
(3.7–4.6)
4.1 ± 0.5
(3.7–5.0)
4.1 ± 0.5
(3.4–5.0)
3.7 ± 0.4
(3.4–4.6)
Serum calcium,
mean ± SD
(range) (mg/dL)
9.8 ± 0.4
(9.2–10.4)
9.8 ± 0.2
(9.6–10.0)
9.9 ± 0.2
(9.6–10.4)
9.7 ± 0.3
(9.2–10.0)
9.7 ± 0.2
(9.6–10.0)
9.9 ± 0.2
(9.6–10.0)
Notes: Data are presented as n (%), unless otherwise stated. Data relate to the safety population (with the exception of serum phosphorus
and calcium, which are from the pharmacodynamic population) in all study groups.
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Table 3. Baseline characteristics with lanthanum carbonate (LC) at a dose of 3000 mg/day of elemental lanthanum.
Study
Parameter Study 1 Study 2 Study 3a Study 4 Study 5
n 10 56 52 57 6
Age, mean ± SD
(range) (years)
25.4 ± 5.2
(20–37)
25.2 ± 5.0
(18–40)
23.3 ± 3.2
(18–31)
29.2 ± 10.8
(18–55)
23.3 ± 1.8
(21–26)
Gender
Male 6 (60.0) 27 (48.2) 25 (48.1) 37 (64.9) 6 (100)
Female 4 (40.0) 29 (51.8) 27 (51.9) 20 (35.1) –
Race
Caucasian 9 (90.0) 54 (96.4) 46 (88.5) 12 (21.1) –
Black 0 (0) 0 (0) 3 (5.8) 9 (15.8) –
Asian 1 (10.0) 1 (1.8) 1 (1.9) 8 (14.0) 6 (100)
Other 0 (0) 1 (1.8) 2 (3.8) 28 (49.1) –
Weight, mean ± SD
(range) (kg)
72.3 ± 12.6
(54–92)
68.4 ± 10.8
(50–95)
67.2 ± 9.0
(47–95)
72.6 ± 12.4
(47.2–106.8)
60.2 ± 6.5
(54–72)
Serum creatinine,
mean ± SD
(range) (mg/dL)
Not recorded 0.91 ± 0.11
(0.6–0.9)
A: 0.82 ± 0.11 (0.7–1.0)
B: 0.84 ± 0.15 (0.6–1.1)
0.95 ± 0.23
(0.5–1.8)
1.03 ± 0.08
(1.0–1.2)
Serum phosphorus,
mean ± SD
(range) (mg/dL)
4.1 ± 0.4
(3.7–4.6)
3.6 ± 0.5
(2.5–4.6)
A: 3.1 ± 0.4 (2.2–4.0)
B: 3.1 ± 0.5 (1.5–4.0)
3.6 ± 0.5
(2.5–5.0)
3.7 ± 0.3
(3.3–4.2)
Serum calcium,
mean ± SD
(range) (mg/dL)
9.9 ± 0.2
(9.6–10.4)
9.9 ± 0.4
(9.2–10.8)
A: 10.1 ± 0.3 (9.6–10.8)
B: 10.0 ± 0.4 (9.2–10.8)
9.7 ± 0.3
(8.6–10.4)
9.1 ± 0.3
(8.7–9.3)
Notes: Data are presented as n (%), unless otherwise stated. Data relate to the safety population in all studies with the exception of
phosphorus and calcium data for study 1; studies 2, 3, and 4 were crossover studies; study 1 only included patients receiving a daily dose
of 3000 mg LC; and study 5 only included patients receiving LC.
aPatients in arm A received 4 × 250 mg LC tablets ﬁrst, those in arm B received 1 × 1000 mg LC tablet ﬁrst.
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Figure 1. Mean ± SD reduction from baseline in average daily
urinary phosphorus excretion at different doses of lanthanum
carbonate (study 1).
formulation, 10 (20%) volunteers receiving the exist-
ing (2 × 500 mg tablets) formulation, and 10 (19%)
volunteers receiving the optimal (1 × 1000 mg tablets)
formulation. In study 3, headache was experienced by
two (4%) individuals receiving 4 × 250 mg tablet dosing
and six (12%) individuals receiving 1000 mg tablet dos-
ing. Nausea was experienced by two (4%) participants
receiving 250 mg tablets and by three (6%) participants
receiving 1000 mg tablets. One (2%) participant receiv-
ing 250 mg tablets and three (6%) participants receiving
1000 mg tablets experienced abdominal pain. In study
4, the most frequently reported adverse events were
headache [two (4%) participants receiving batch A and
ﬁve (10%) participants receiving batch B] and dizziness
[three (6%) participants receiving batch A and two (4%)
participants receiving batch B]. Dyspepsia was experi-
enced by three (6%) volunteers receiving batch A but no
one receiving batch B and pharyngolaryngeal pain was
experienced by no participants receiving batch A but
three (6%) participants receiving batch B. There were
no adverse events in study 5.
DISCUSSION
Control of phosphate overload in patients with CKD
is now recognized as an important target for reducing
the high mortality rate associated with this condition9,10
and current practice guidelines recommend aggressive
treatment of hyperphosphatemia to achieve lower serum
phosphorus targets.11
The Kidney Disease Outcomes Quality Initiative
nutritional guidelines recommend maintenance of pro-
tein intake at 1.2 g/kg body weight per day for hemodial-
ysis patients.12 With an average phosphate content of
10–12 mg/g protein, a 70 kg patient should therefore
consume 840–1008 mg phosphate (27.1–32.5 mmol
elemental phosphorus) per day.11 Based on the con-
servative estimate that 60% of ingested phosphate
is absorbed from the gastrointestinal tract,13 a typi-
cal hemodialysis patient will absorb up to 4200 mg
(135.5 mmol) phosphate per week. As thrice-weekly
hemodialysis will only remove approximately 2400 mg
(77.4 mmol) phosphate,11 absorption of approximately
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Table 4. Reduction in 24-h urinary phosphorus excretion from baseline with lanthanum carbonate (LC) at a dose of 3000 mg/day of
elemental lanthanum.
Urinary phosphorus excretion, mg/day (mmol/day)
Study and formulation
(all given three times daily) At baseline At end point
Reduction from
baseline
Study 1 (n = 9)
1 × 1000 mg tablet 992±253 (32.0 ± 8.2) 662±154 (21.4 ± 5.0) 329±276 (10.6 ± 8.9)
Study 2 (n = 47)
4 × 250 mg tablets 592±233 (19.1 ± 7.5) 353±133 (11.4 ± 4.3) 239±183 (7.7 ± 5.9)
2 × 500 mg tablets 663±252 (21.4 ± 8.1) 370±164 (11.9 ± 5.3) 294±177 (9.5 ± 5.7)
1 × 1000 mg tablet 674±310 (21.8 ± 10.0) 356±144 (11.5 ± 4.6) 318±294 (10.3 ± 9.5)
Study 3 (n = 48)
4 × 250 mg tablets 637±195 (20.6 ± 6.3) 393±130 (12.7 ± 4.2) 244±164 (7.9 ± 5.3)
1 × 1000 mg tablet 646±167 (20.8 ± 5.4) 410±142 (13.2 ± 4.6) 236±167 (7.6 ± 5.4)
Study 4 (n = 33)
Batch A (4 × 250 mg tablets) 952±155 (30.7 ± 5.0) 643±116 (20.7 ± 3.7) 309±149 (10.0 ± 4.8)
Batch B (4 × 250 mg tablets) 921±177 (29.7 ± 5.7) 641±143 (20.7 ± 4.6) 279±168 (9.0 ± 5.4)
Study 5 (n = 6)
4 × 250 mg tablets 680±211 (21.9 ± 6.8) 212±99 (6.8 ± 3.2) 468±167 (15.1 ± 5.4)
Notes: Data relate to the pharmacodynamic populations; studies 2, 3, and 4 were crossover studies; study 1 only included patients
receiving a daily dose of 3000 mg LC; and study 5 only included patients receiving LC. In study 4, batch A: optimized formulation; batch
B: alternative formulation. Data are mean ± SD.
1800 mg (58.1 mmol) phosphate per week must be
prevented to achieve neutral phosphate balance.
Recommended protein intake is slightly higher for
peritoneal dialysis patients (1.2–1.3 g/kg bodyweight per
day)11 compared with their counterparts on hemodial-
ysis. A 70 kg peritoneal dialysis patient may therefore
consume up to 1092 mg phosphate (35.3 mmol ele-
mental phosphorus) per day, resulting in absorption of
4586 mg (148.1 mmol) phosphate per week (assum-
ing 60% absorption13). As peritoneal dialysis removes
only about 315 mg (10.2 mmol) phosphate per day,11
absorption of approximately 2381 mg (76.9 mmol)
phosphate per week must be prevented by other means
to prevent phosphate overload.
In reality, the dietary phosphate intake of many
dialysis patients is likely to be closer to the typical
US daily phosphate intake of 1300 mg (41.9 mmol
elemental phosphorus) per day14; furthermore, the
gastrointestinal tract may absorb up to 86% of ingested
phosphate depending on vitamin D status.13 Add to this
the problem of phosphate-based food additives that are
better absorbed than the phosphates found in unpro-
cessed foods,15 and the phosphate burden could be
signiﬁcantly higher than the above estimates.
Effective dietary phosphate binders are therefore
desirable to prevent phosphate overload.7,16 In our
studies in healthy volunteers, lanthanum (given as
LC) reduced urinary phosphorus excretion at all
doses tested; 3000 mg/day produced a near-maximal
response, with saturation occurring at higher doses.
These results are consistent with clinical practice where
doses of 2250–3000 mg/day appear to be effective for
management of hyperphosphatemia.
The data reported here suggest that the standard
1000 mg dose of LC reduces mean 24-h urinary phos-
phorus excretion by between 79 and 156 mg/day (2.5
and 5.0 mmol/day) in healthy volunteers (data from
Table 4 and Figure 1). In the studies in which they
were directly compared, the different LC formulations
were shown to be pharmacodynamically equivalent and
there were no notable differences between the formu-
lations. There was some inner study variation despite
the same LC dose, probably due to differences in
study procedures, the race of participants,17 geograph-
ical location,18 the standardized phosphate content of
diets, and potentially the type of phosphate (organic vs.
inorganic) found in these diets.19 The largest reduction
in 24-h urinary phosphorus excretion was experienced
in the Japanese participants in study 5. A recent study
has shown racial differences in the renal handling of
phosphate between Caucasian and Black individuals17;
phosphate handling may also be different in Asian popu-
lations. The use of a standardized diet with similar phos-
phate content to that of the other studies in Japanese
individuals with a lower body mass (Table 3) may also
have affected phosphate handling. Geographic and sea-
sonal differences in ultraviolet light exposure across
study populations may also have resulted in different
vitamin D status,18 potentially inﬂuencing phosphate
absorption.
A typical hemodialysis patient may require removal
of about 1800 mg (58.1 mmol) of phosphate by
binders every week, or approximately 257 mg/day
(8.3 mmol/day). Our data suggest that a 1000 mg
dose of LC binds 79–156 mg (2.5–5.0 mmol) phos-
phate; therefore, approximately 1650–3250 mg/day LC
would be required to remove a typical phosphate bur-
den. This range correlates reasonably well with clinical
experience, as LC doses of 2250–3000 mg/day (typi-
cally three tablets per day) appear to be sufﬁcient for
management of hyperphosphatemia in the majority of
patients.
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Several studies have examined the binding capaci-
ties of other phosphate binders in healthy volunteers.
While comparisons across these studies cannot provide
robust evidence, they provide useful indications regard-
ing the relative phosphate-binding capacities of LC and
other binders. Burke et al.5 administered various doses
of SH to healthy volunteers (n = 6 per group) receiv-
ing a standardized diet (1200 mg elemental phosphorus,
similar to most of our studies). Compared with placebo,
SH 1000, 2500, and 5000 mg administered three times
daily reduced urinary phosphorus excretion by 108
mg/day (3.4 mmol/day), 245 mg/day (7.7 mmol/day),
and 340 mg/day (10.6 mmol/day), respectively. There-
fore, the apparent phosphate-binding capacity of seve-
lamer decreased with increasing dose, similar to LC
doses greater than 1000 mg three times per day in study
1. A single 1000 mg dose of SH (the most effective dose
per gram of binder in the Burke study) was estimated to
result in a reduction in mean 24-h urinary phosphorus
of approximately 36 mg/day (1.2 mmol/day), equivalent
to 29 mg/day (0.9 mmol/day) per 800 mg tablet. No
published data on the binding capacity of the alternative
sevelamer carbonate formulation compared with SH are
available.
Phosphorus recovered in urine over 6 h after a
1000 mg (32.3 mmol) phosphorus load and administra-
tion of calcium phosphate binders has been assessed in
six healthy volunteers.20 Dosing with two calcium car-
bonate tablets (800 mg of elemental calcium) resulted
in a decrease in urinary phosphorus excretion of 31
mg (1.0 mmol) compared with control, whereas six
calcium acetate tablets reduced urinary phosphorus by
132 mg (4.3 mmol) [22 mg (0.71 mmol) per tablet]. In
another study21 the calculated reduction in 24-h urinary
excretion of phosphate after 6 days of treatment was
66 mg (2.1 mmol) per 1000 mg of elemental calcium
compared with 32 mg (1.0 mmol) per 1000 mg of SH.
Following consumption of a set meal (daily elemen-
tal phosphorus intake of 1000 mg in three meals),
net phosphorus absorption was determined based on
fecal phosphorus excretion.16 In this study, 1000 mg
of elemental calcium (given as calcium acetate) bound
174 mg (5.6 mmol) of phosphorus [equating to 29 mg
(0.9 mmol) per tablet], whereas the same elemental
dose of calcium given as the carbonate bound 112 mg
(3.6 mmol) of phosphate. Calcium citrate bound 92 mg
(3.0 mmol) of phosphorus per 1000 mg of elemen-
tal calcium and aluminum carbonate bound 155 mg
(5.0 mmol) of phosphorus per 1000 mg of elemental
aluminum.
Only indirect comparisons of phosphate-binding
capacity can be made based on our studies and the
published literature. To bind the 257 mg/day (8.3
mmol/day) excess phosphate from a dietary intake of
1000 mg/day (32.3 mmol/day), a hemodialysis patient
may theoretically require approximately three LC (3000
mg elemental lanthanum) tablets, nine calcium acetate
tablets (1521 mg elemental calcium), or nine SH
tablets (7200 mg SH). These calculations are consistent
with manufacturers’ dosage recommendations22–24 and
reﬂect clinical practice where phosphate binders often
contribute 50% of total daily tablet burden, which may
exceed 25 tablets per day in some patients.25
The proposition that urinary phosphorus excretion is
an index for phosphate binding assumes that the indi-
vidual is at steady state. Little is known about the time
effects of phosphate binders on net phosphate absorp-
tion. Calcium absorption has been better studied; it
takes between 10 and 17 days to achieve a new steady
state after a change in calcium intake.26 Phosphate may
achieve steady state more rapidly because the renal
mechanism for phosphate conservation is more respon-
sive to phosphatonins and does not require new protein
synthesis. Thus, short-term studies serve as an effective
estimate of the relative magnitude of phosphate bind-
ing by various agents, but unless studies occur within
the same individuals under identical conditions, the
results should only be used as a ﬁrst estimate of rela-
tive binding capacity. Thus, there are clear limitations
when comparing data from different studies and a direct
comparison of phosphate binders in healthy volunteers
is required. It should be noted, however, that patients
with CKD may differ from healthy individuals in terms
of gastrointestinal absorption dynamics, such as tran-
sit times, effects of pH on binding and absorption, and
drug interactions. Relative phosphate-binding capacities
in individuals with CKD may therefore differ from those
established in studies in healthy volunteers.
In conclusion, LC effectively reduces absorption
of dietary phosphate in healthy individuals. Clinicians
should consider the dose–response relationship for the
different phosphate binders when reviewing doses or
choice of binder. A direct comparison of the bind-
ing capacities of currently available phosphate binders
would be useful to guide clinical practice.
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